CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) Q4 2024 Earnings Call Transcript March 26, 2025 CollPlant Biotechnologies Ltd.

CEO Yehiel Tal highlighted advancements in CollPlant's proprietary photocurable dermal filler, emphasizing its potential as a game-changer in the $6.3 billion market for aesthetic medicine.

Discover CollPlant Biotechnologies' Q4 2024 earnings insights, including advancements in regenerative implants and fillers.

CollPlant Biotechnologies , or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue ...

This past year to date, we have progressed on all fronts – from advancing our collaborative programs, to gaining momentum on our proprietary ...

Wisteria should be pruned regularly and is better suited for growing on a strong arbor or trellis. Roses are incredibly romantic, so why shouldn't you plant a line of shrubby roses or a trellised ...

In 2021 I wrote an article discussing ‘deflating faces‘ – a reference towards celebrities dissolving their dermal fillers. It’s safe to say that, after four years, ‘filler fatigue’ is still trending.